Regenerative Medicine Insights

A study published in Bone found that stem cells from younger donors could divide more times, divided faster, and showed signs of cellular aging later than cells from older donors. While the study was small and conducted in the lab, it highlights a fundamental idea: our stem cells age with us—and we can’t go back later to recover the younger cells we once had.

Saving your body's repair cells just got much easier. A new partnership makes it

RYC Orthopaedics PA Jenna Trainor on regenerative medicine, orthobiologics, and proactive care with Forever Labs

Japan conditionally approves stem cell treatments for Parkinson’s and heart failure. Clinical trials show significant functional recovery, shifting from managing symptoms to restoring health.

Turn your aesthetic procedure into a milestone for longevity. Discover how to bank your own stem cells during liposuction or skin reduction to power your future health and healing.

From CRISPR to cord blood, explore how six women are pioneering and moving medicine toward a proactive, evidence-based future of recovery.

On the Future Proof with Forever Labs podcast, Drs. Tad DeWald and Brett Fox talk about proactive prehab and regenerative medicine. They promote a 50/50 partnership between clinical care and personal movement to future-proof your physical health.

Discover how Forever Labs and Michigan Center for Regenerative Medicine are growing access to advanced stem cell storage and expansion to the U.S., offering personalized, high-dose regenerative treatments for long-term joint health and recovery.

You can now fix knee and back pain without major surgery. This new treatment uses lasers and your own repair cells to help your body heal naturally so you can get back to moving comfortably.

Mary Shaver, a 35-year-old nurse, shares her experience banking her stem cells with Forever Labs. She details why she chose to preserve her youth today to protect her health for the future.

Forever Labs CEO Kevin Virgil avoided knee surgery by using his own banked stem cells to treat osteoarthritis, returning to trail running and proving the power of biological insurance.

In the latest Future Proof with Forever Labs episode, Dr. Trevor Turner shares the latest on regenerative orthopedics at CartiNova. Discover how to move beyond pain management to genuine joint repair, securing lifelong mobility with banked stem cells and more.

Wyoming’s Senate File 48, the Stem Cell Freedom Act, proposes a legal framework for physicians to perform autologous stem cell therapies under IRB oversight and cGMP safety standards.

MSC Therapy for Heart Disease: Regenerative approach with Mesenchymal Stem Cells to restore cardiac function. Studies like DREAM-HF show a 58% reduced risk of heart attack, moving beyond symptom management.

New laws are being proposed to make it easier for you to use your own stem cells for healing. This means you could access new treatments for injuries or pain much faster, using your body's own repair cells to help you get well.

Your body's repair cells send out tiny "healing packages" that can help fix a heart after a heart attack. New medical studies show that using special patches to keep these packages in place helps the heart heal much faster.

Using your own blood during surgery can help keep your mind clear and sharp while you recover. This study shows that using your own cells instead of a donor's reduces the risk of confusion and helps you heal faster.

Beast Games star and matchmaker Tessa Mac shares her powerful journey into regenerative medicine, sparked by a friend’s cancer battle and solidified by her own "aha" moment regarding biological insurance. In the inaugural episode of Future Proof with Forever Labs podcast, she shares why she decided to freeze her Mesenchymal Stem Cells (MSCs) as the ultimate "low-hanging fruit" for long-term health. From setting world records to surviving California wildfires, Tessa explains how securing her youngest, healthiest cells allows her to live a high-octane life today with zero regrets for tomorrow.

Explore Forever Labs's outlook on 2026 trends in regenerative medicine. Longevity has transitioned from biohacking to a mainstream standard of care. Discover breakthroughs in "bio-liquidity", MSC priming, and epigenetic resetting, alongside regulatory shifts in the United States empowering patients to own their biology.

Why freezing your young stem cells matters today. Bank your young Mesenchymal Stem Cells (MSCs) today to secure a high-potency, genetically-matched 'medical reserve' for your future. Research shows that younger MSCs offer enhanced healing, boost cognitive function, and are linked to extended healthspan, providing an ideal resource for future regenerative therapies while eliminating the risk of immune rejection.

As of early 2026, the landscape for regenerative medicine has undergone a transformative shift, moving from a period of experimental storage to one of clinical accessibility. For individuals who have invested in stem cell banking, the bridge to active therapy is now open, supported by landmark state legislation and new domestic manufacturing capabilities.

Stem cell research is transitioning from theory to clinical reality, with over 750 recent trials targeting conditions like osteoarthritis and heart disease. While global adoption grows, many Americans remain hesitant due to common misconceptions. Self-derive stem cell therapy is legal in the U.S. when minimally manipulated, poses low rejection risks, and avoids ethical issues by using adult cells rather than embryos. Compared to surgery, these treatments are minimally invasive with faster recovery times. Companies like Forever Labs now offer biobanking, allowing individuals to preserve their young cells for future longevity treatments.

A 2025 prospective observational study tested whether a single administration of **adipose-derived mesenchymal stem cells (ADSCs)** produces immediate changes in blood markers and muscle strength in people with neurodegenerative and respiratory conditions. The study measured serum cholinesterase ...

MSC-derived exosomes (tiny cell-made vesicles) can cross the blood–brain barrier and deliver regenerative signals that MSCs themselves can’t. In animal Alzheimer’s models, they boosted neurotrophic factors like BDNF and NGF (supporting neuron growth/survival), reduced pro-inflammatory molecules, and were associated with less amyloid plaque buildup and better performance on memory/cognition tasks. Early human trials are still small and preliminary, but so far look generally tolerable and show hints of reduced inflammation—meaning it’s promising, but not yet proven or ready as a standard treatment.

Something important changed in Florida on July 1: the state passed a law (Senate Bill SB‑1768) that allows licensed physicians to offer certain stem cell treatments that are not yet FDA-approved — but only for specific uses (orthopedics, wound care, and pain management) and only if strict rules a...

This large single-center study looked at outcomes when people with relapsed multiple myeloma received a second autologous hematopoietic cell transplant (autoHCT) either later in their disease course ("delayed") or as a planned salvage treatment. The team reviewed 650 patients treated from 2006–20...

New findings show that certain circular RNAs can help control how your body's repair cells turn into different types of cells, which is important for healing and growth. This could lead to better treatments for conditions like osteoporosis and muscle loss. Understanding these processes may improve future healing therapies.

Newly modified plant compounds called pentacyclic triterpenes could offer better treatments for diseases like cancer and diabetes by improving how well they work in the body. These changes make them easier for our bodies to use, potentially leading to more effective healing options in the future.

New findings reveal that the germ cell nuclear factor (GCNF) plays a crucial role in neural stem cell development by suppressing Oct4, a key gene for maintaining pluripotency. This regulation is vital for the transition of primitive neural stem cells to definitive ones, potentially unlocking new avenues for regenerative therapies in neurodegenerative diseases.

New findings reveal that the p53 protein is essential for guiding stem cells to differentiate safely, potentially reducing cancer risks. By reactivating p53, researchers could enhance stem cell therapies and develop innovative cancer treatments, paving the way for safer regenerative medicine.

New research highlights the critical role of insulin-like growth factor 1 receptor (IGF1R) in enhancing stem cell self-renewal and therapeutic potential. Understanding IGF1R signaling could significantly improve regenerative treatments, making stem cell preservation more valuable for future health needs.

Hair follicles contain several kinds of stem cells. One group, called hair follicle-associated‑pluripotent (HAP) stem cells, sits in the bulge region of the follicle and expresses the protein nestin. Laboratory studies show HAP cells can turn into many different cell types — neurons, glial cells (support cells in nerves), skin cells, smooth muscle, heart muscle, pigment cells and more [2,10,19,25]. HAP cells are easy to collect from the scalp, do not require genetic reprogramming, do not form tu

Authors: Isabel Dorn, Katharina Klich, Marcos J Arauzo-Bravo, Martina Radstaak, Simeon Santourlidis, Foued Ghanjati, Teja F Radke, Olympia E Psathaki, Gunnar Hargus, Jan Kramer, Martin Einhaus, Jeong Beom Kim, Gesine Kogler, Peter Wernet, Hans R Scholer, Peter Schlenke, Holm Zaehres

Loss or severe damage of the corneal epithelium (the clear, outer surface of the eye) can cause vision loss. Donor tissue for direct corneal or limbal epithelial transplantation is limited, and allogeneic grafts carry a rejection risk. Researchers are developing ways to turn a patient’s own stem cells into corneal epithelial cells for transplantation. This review summarizes what works so far with human stem cells — especially mesenchymal stem/stromal cells (MSCs) and pluripotent stem cells (ESCs

Authors: Stefano Manodoro, Matteo Frigerio, Marta Barba, Sara Bosio, Luigi Antonio de Vitis, Anna Maria Marconi

Authors: M. Mashayekhi et al. (published Jan 6, 2021)

Jesmine Banu; Nishat Jahan; Shaheen A. Anwary; Mostafa Tarique; Itrat Aziz; Nastaran Laskar; M. Rifat Hasan; Chowdhury F. Alamgir; Maliha Darmini

Neeta Singh, Bhawani Shekhar, Sujata Mohanty, Sunesh Kumar, Tulika Seth, Bhavana Girish

Authors: Michael Mitterberger et al.

Authors: Yizhen Sima & Yisong Chen (original review published Cell & Bioscience, 2020)

Pelvic floor disorders (PFDs) — such as stress urinary incontinence (SUI), anal (fecal) incontinence, and pelvic organ prolapse — result from weakness or injury to muscles, nerves, or connective tissues of the pelvic floor. Traditional treatments (rehabilitation, surgery) often give incomplete relief. Stem cell (SC) therapy is being tested as a regenerative alternative.

Authors: Mahta Hadidi, Keyvan Karimabadi, Elham Ghanbari, Leila Rezakhani*, Mozafar Khazaei*

BioCardia announced that the University of Wisconsin School of Medicine and Public Health enrolled its first patient in the Phase 3 CardiAMP HF II trial. This trial is testing CardiAMP, an autologous (patient’s own) bone marrow cell therapy, in people with ischemic heart failure with reduced ejection fraction (HFrEF) who still have signs of heart stress despite optimized medical care.

The authors show that bone marrow–derived mesenchymal stem cells (BM-MSC) can reverse stroke-induced thymic atrophy, restore thymic structure, and normalize peripheral T-cell populations in a mouse tMCAO model.

Muse stem cells are naturally occurring, stress-resistant pluripotent cells that can home to damaged tissues and regenerate without forming tumors, making them a promising and safer option in regenerative medicine. Early clinical trials target

PCOS (primary topic) and emerging stem cell-based treatments (MSC, extracellular vesicles, exosomes), including a human case report and ongoing clinical trials. It emphasizes fertility/reproductive implications, metabolic (insulin resistance) aspects of PCOS, and the proposition of banking stem cells.

New Hampshire House Bill 701 establishes the Terminal Patients' Right to Try Act, providing legal pathways for terminally ill patients to access experimental treatments including regenerative therapies.

The Federation of State Medical Boards provides comprehensive guidelines for regenerative therapy practices, establishing standards for physician training, patient safety, and regulatory compliance across state medical boards.

Utah Senate Bill SB0199 introduces amendments to existing regulations regarding placental tissue use in medical treatments, clarifying legal frameworks for regenerative medicine applications.

Montana Legislative Bill LC0780/SB535 establishes frameworks for experimental treatment centers, providing pathways for innovative medical treatments including regenerative therapies under controlled conditions.

Florida HB 1617 authorizes physicians to perform FDA-unapproved stem cell therapy with specific requirements for manufacturing practices, patient consent, and advertising disclosures. Effective July 1, 2025.

AIMS: Regenerative treatment with mesenchymal stromal cells (MSCs) has been promising in patients with ischaemic heart failure but needs confirmation in larger randomized trials. We aimed to study effects of intra-myocardial autologous bone marrow-derived MSC treatment in patients with severe ischaemic heart failure. __METHODS AND RESULTS__ The MSC-HF trial is a randomized, double-blind, placebo-controlled trial. Patients were randomized 2 : 1 to intra-myocardial injections of MSC or placebo, respectively. The primary endpoint was change in left ventricular end-systolic volume (LVESV), measured by magnetic resonance imaging or computed tomography at 6 months follow-up. Sixty patients aged 30-80 years with severe ischaemic heart failure, New York Heart Association (NYHA) classes II-III, left ventricular ejection fraction (LVEF) <45% and no further treatment options were randomized. Fifty-five patients completed the 6-month follow-up (37 MSCs vs. 18 placebo). At 6 months, LVESV was reduced in the MSC group: -7.6 (95% CI -11.8 to -3.4) mL (P = 0.001), and increased in the placebo group: 5.4 (95% CI -0.4 to 11.2) mL (P = 0.07). The difference between groups was 13.0 (95% CI 5.9-20.1) mL (P = 0.001). Compared with placebo, there were also significant improvements in LVEF of 6.2% (P<0.0001), stroke volume of 18.4 mL (P < 0.0001), and myocardial mass of 5.7 g (P = 0.001). No differences were found in NYHA class, 6-min walking test and Kansas City cardiomyopathy questionnaire. No side effects were identified. __CONCLUSION__ Intra-myocardial injections of autologous culture expanded MSCs were safe and improved myocardial function in patients with severe ischaemic heart failure.

A meta-analysis of 18 clinical trials (565 patients) demonstrates that mesenchymal stem cell (MSC) therapy significantly improves pain (VAS) and knee function (IKDC, Lysholm, WOMAC) in osteoarthritis patients, with sustained efficacy up to 24 months and peak benefits at 12-24 months post-treatment. Outcomes were enhanced by arthroscopic debridement, activation agents, and lower Kellgren-Lawrence grades, but showed no dose-response to MSC numbers. MSC treatment offers promising pain relief and functional gains for knee osteoarthritis.

While mesenchymal stem cells represent an interesting cell source for regenerative medicine, several points have to be investigated to improve their use in clinical, and in particular in the elderly population. This work studied the proliferation capacity of mesenchymal stem cells isolated from human bone marrow in function of donor's age. Doubling time after in vitro culture, clonogenicity and phenotype were analyzed in 17 samples ranging from 3 to 85 years old (mean 47 ± 27). Results showed an increase in the doubling time for cell coming from old donor compared to cells coming from young ones. This was accompanied by a decrease in clonogenicity while no changes were observe in cell phenotype. In conclusion, this study showed an effect of donor's age on the proliferation capacity of mesenchymal stem cells isolated from bone marrow that was correlated to a decrease in clonogenicity. The comprehension of molecular mechanism involved in this process could help to improve the clinical application of mesenchymal stem cells.

Aging is a complex process of damage accumulation, and has been viewed as experimentally and medically intractable. The number of patients with age-associated diseases such as type 2 diabetes mellitus (T2DM), osteoporosis, Alzheimer's disease (AD), Parkinson's disease, atherosclerosis, and cancer has increased recently. Aging-related diseases are related to a deficiency of the immune system, which results from an aged thymus and bone marrow cells. Intra bone marrow-bone marrow transplantation (IBM-BMT) is a useful method to treat intractable diseases. This review summarizes findings that IBM-BMT can improve and treat aging-related diseases, including T2DM, osteoporosis and AD, in animal models.

__Increasing evidence suggests that the loss of functional stem cells may be important in the aging process.__ Our experiments were originally aimed at testing the idea that, in the specific case of age-related osteoporosis, declining function of osteogenic precursor cells might be at least partially responsible. To test this, aging female mice were transplanted with mesenchymal stem cells from aged or young male donors. We find that transplantation of young mesenchymal stem cells significantly slows the loss of bone density and, surprisingly, prolongs the life span of old mice. These observations lend further support to the idea that age-related diminution of stem cell number or function may play a critical role in age-related loss of bone density in aging animals and may be one determinant of overall longevity.

This study confirms that long-term cryopreservation of bone marrow for up to 7.8 years does not negatively impact hematopoietic stem cell viability or engraftment success. Results indicate that early-stage marrow collection can effectively preserve stem cell quality before cumulative damage from chemotherapy or radiation occurs. This research supports the long-term storage of autologous bone marrow as a reliable option for future transplantation.

Tissue renewal is a well-known phenomenon by which old and dying-off cells of various tissues of the body are replaced by progeny of local or circulating stem cells (SCs). An interesting question is whether donor SCs are capable to prolong the lifespan of an aging organism by tissue renewal. In this work, we investigated the possible use of bone marrow (BM) SC for lifespan extension. To this purpose, chimeric C57BL/6 mice were created by transplanting BM from young 1.5-month-old donors to 21.5-month-old recipients. Transplantation was carried out by means of a recently developed method which allowed to transplant without myeloablation up to 1.5 × 10(8) cells, that is, about 25% of the total BM cells of the mouse. As a result, the mean survival time, counting from the age of 21.5 months, the start of the experiment, was +3.6 and +5.0 (±0.1) months for the control and experimental groups, respectively, corresponding to a 39 ± 4% increase in the experimental group over the control. In earlier studies on BM transplantation, a considerably smaller quantity of donor cells (5 × 10(6)) was used, about 1% of the total own BM cells. The recipients before transplantation were exposed to a lethal (for control animals) X-ray dose which eliminated the possibility of studying the lifespan extension by this method.

As human lifespan increases, a greater fraction of the population is suffering from age-related cognitive impairments, making it important to elucidate a means to combat the effects of aging. Here we report that exposure of an aged animal to young blood can counteract and reverse pre-existing effects of brain aging at the molecular, structural, functional and cognitive level. Genome-wide microarray analysis of heterochronic parabionts--in which circulatory systems of young and aged animals are connected--identified synaptic plasticity-related transcriptional changes in the hippocampus of aged mice. Dendritic spine density of mature neurons increased and synaptic plasticity improved in the hippocampus of aged heterochronic parabionts. At the cognitive level, systemic administration of young blood plasma into aged mice improved age-related cognitive impairments in both contextual fear conditioning and spatial learning and memory. Structural and cognitive enhancements elicited by exposure to young blood are mediated, in part, by activation of the cyclic AMP response element binding protein (Creb) in the aged hippocampus. Our data indicate that exposure of aged mice to young blood late in life is capable of rejuvenating synaptic plasticity and improving cognitive function.

Bone marrow-derived stem cells may modulate renal injury, but the effects may depend on the age of the stem cells. Here we investigated whether bone marrow from young mice attenuates renal aging in old mice. We radiated female 12-mo-old 129SvJ mice and reconstituted them with bone marrow cells (BMC) from either 8-wk-old (young-to-old) or 12-mo-old (old-to-old) male mice. Transfer of young BMC resulted in markedly decreased deposition of collagen IV in the mesangium and less β-galactosidase staining, an indicator of cell senescence. These changes paralleled reduced expression of plasminogen activator inhibitor-1 (PAI-1), PDGF-B (PDGF-B), the transdifferentiation marker fibroblast-specific protein-1 (FSP-1), and senescence-associated p16 and p21. __Tubulointerstitial and Glomerular Cells__ Tubulointerstitial and glomerular cells derived from the transplanted BMC did not show β-galactosidase activity, but after 6 mo, there were more FSP-1-expressing bone marrow-derived cells in old-to-old mice compared with young-to-old mice. Young-to-old mice also exhibited higher expression of the anti-aging gene Klotho and less phosphorylation of IGF-1 receptor β. Taken together, these data suggest that young bone marrow-derived cells can alleviate renal aging in old mice. Direct parenchymal reconstitution by stem cells, paracrine effects from adjacent cells, and circulating anti-aging molecules may mediate the aging of the kidney.

Human bone marrow-derived mesenchymal cells contain mesenchymal stem cells (MSCs), which are well known for their osteo/chondrogenic potential and can be used for bone reconstruction. This article reports the viability of cryopreserved human mesenchymal cells and a comparison of the osteogenic potential between noncryopreserved and cryopreserved human mesenchymal cells with MSC-like characteristics, derived from the bone marrow of 28 subjects. The viability of cryopreserved mesenchymal cells was approximately 90% regardless of the storage term (0.3 to 37 months). It is clear by fluorescence-activated cell sorter analysis that the cell surface antigens of both noncryopreserved and cryopreserved mesenchymal cells were negative for hematopoietic cell markers such as CD14, CD34, CD45, and HLA-DR but positive for mesenchymal characteristics such as CD29 and CD105. To monitor the osteogenic potential of the cells, such as alkaline phosphatase (ALP) activity and in vitro mineralization, a subculture was conducted in the presence of dexamethasone, ascorbic acid, and glycerophosphate. No difference in osteogenic potential was found between cells with or without cryopreservation treatment. In addition, cells undergoing long-term cryopreservation (about 3 years) maintained high osteogenic potential. In conclusion, cryopreserved as well as noncryopreserved human mesenchymal cells could be applied for bone regeneration in orthopedics.

Forget aging by accident. Forever Labs lets you bank your younger stem cells today to fuel your health tomorrow. Because when it comes to your biology, your best donor is a younger version of you.

Recent research in gerontology shows that injecting young bone marrow into older mice can increase their remaining lifespan by up to 39%. While these findings highlight the exciting potential of regenerative medicine for life extension, further study is needed to determine how these biological mechanisms translate to human aging.

Aren't iPS cells the future. When talking to friends, colleagues, and others about Forever Labs, those among them with a certain level of knowledge in the biosciences often turn the conversation to iPS cells.

What happens to your cells as they age. The answer is complex and imperfectly understood.

What is a stem cell anyway. As a biologist, and one who works with bone marrow stem cells in daily life, it’s easy to forget that to the general public, a ‘stem cell’ is not much more than an abstraction, a news-worthy meme that comes light on the details.

Bone marrow vs. adipose MSCs There is an ongoing debate among stem cell therapy proponents about what the best source of cells is.

New Studies Show How Donor Age Affects MSCs’ Disease Fighting Capabilities In the past, I’ve written that there is a strong suggestion that MSCs from older individuals are less likely than those from young ones to fight diseases, but that the evidence—though strong—is mainly circumstantial. However, two very recent studies have shown direct and convincing evidence that this is indeed the case.

Stanford University researcher Tony Wyss-Coray explores groundbreaking research into how young blood and cellular factors can potentially reverse the effects of aging on the human brain and body. This insight into regenerative medicine suggests that internal biological triggers may be the key to revitalizing cognitive health and physical longevity.

Cellular Senescence in Brief Forever Labs was founded on the principle that each of us has a valuable reservoir of bone marrow cells, and that as we age this reservoir is depleted, much like an extended drought that has depleted Lake Powell in the Southwest. Las Vegas and Phoenix grow and grow, it rains less and less, and the river can’t keep the water level high enough to meet demand. I think this is a salient analogy of what happens in our bone marrow as we age.

Do MSCs act exclusively on the immune system in neural injury. An interesting study came to my attention recently.

Why Your Own Cells Matter While donor products could offer temporary relief, your own cryopreserved stem cells can provide a lasting solution for tissue repair. By avoiding immune rejection, "self" cells can fully integrate and heal your body long-term. Learn why storing your youngest and most viable stem cells cells is your best healthcare asset.

Forever Labs physician Dr. Michael Schenden featured on WXYZ Detroit news Last week, Dr.

Three Questions As CEO of Forever Labs, I attend as many of our stem cell collections as I can and I talk with many of our clients. The majority of people that are interested in storing their young-adult stem cells with us have the same three questions.

DigitalCulture.LA's Brittney Gallagher interviews Forever Labs co-founders Steven Clausnitzer and Mark Katakowski on Forever Labs co-founders on adult stem cell storage. The core message: Cryopreserve your healthy stem cells now to "lock in" their youthful vigor before they age, preparing for future medical needs.

Mark Katakowski, President of Forever Labs, presents a Talk at Google on how stem cell rejuvenation could potentially increase human life expectancy by restoring the function of aging

Young donor stem cells improve frailty in a clinical trial: What if they had their own younger cells. In my last blog post, I discussed our plan to transplant our own younger mesenchymal stem cells (MSCs) to our older selves for the purposes of rejuvenation.

Transplanting young stem cells extended old mice's lifespan by 28%, suggesting a path to human rejuvenation.

Overview of MSC therapy for multiple clinical trials, showing broad potential for the clinical use of hMSCs with no reported serious adverse events.

This was a prospective, randomized, double-blind, placebo-controlled trial - which is considered the gold standard for clinical research. Patients used their own stem cells to regenerate damaged heart muscle whose heart failure was caused by blocked coronary arteries (ischemic), showing fewer heart-related complications and better symptoms compared to placebo.

Researchers treated 17 heart attack patients with an infusion of stem cells taken from their own hearts. A year after the procedure, the amount of scar tissue had shrunk by about 50%.

Critical Review of multiple clinical trials using MSCs for heart disease conditions

Over 60% of patients receiving treatment for head and neck cancers experience radiation-induced salivary gland damage. The study suggests this could provide a definitive treatment rather than just symptom management for the millions of people suffering from dry mouth conditions.

The combination of stem cells and niacinimide improved skin through multiple mechanisms - reducing inflammation, protecting collagen structure, promoting collagen production, and enhancing skin repair - resulting in measurable improvements in wrinkles, pigmentation, and overall skin appearance that both patients and doctors could observe.

Hair density and keratin significantly increased after one injection of stem cells.

Both cellular and acellular stem cell–based therapies are safe and effective in improving hair regeneration and density in AGA patients. Although the outcomes may be temporary in some cases, regenerative treatments may become useful adjuncts in combination with traditional methods of hair transplantation.

Study showed the shallowing and disappearance of wrinkles, including those of the glabella, lower eyelids, crow`s feet, and forehead and nasolabial grooves, a month to several months after treatment, with results lasting over a year.

Study confirmed greater clinical improvements in skin wrinkles, elasticity, hydration, and pigmentation on the HACS-treated side than on the control side, proving both safe and effective.

Intramyocardial delivery of stem cells is more complicated than intracoronary administration, but it is safe and may provide better therapeutic outcomes.

Cell-based therapies including pluripotent and multipotent adult stem cells show proven repair and regeneration potential and are being considered as a remedy for diabetic complications, which are the most prominent reason for high mortality among diabetic patients. They may also provide a long-term cure for diabetes and its complications.

No alternative intervention strategies match, or even get close to, the clinical outcome achieved in a considerable number of patients treated with autologous stem cell transplantation. We propose that this patient group should be identified, diligently informed and offered the possible benefits of an extended period of insulin-free and burden-free survival,

Reports summarized here suggest significant potential for the use of mesenchymal stem cells in osteoarthritis.

MSCs offer a promising emerging therapy for patients with IBD due to their immunosuppressive properties, ability to migrate to areas of injury, and demonstration of colonic healing.

Stem cell-based approaches can induce poststroke recovery via mechanisms, such as neuronal replacement, promotion of angiogenesis, induction of brain plasticity, reduction of cell death, or immunomodulation.

This study provides strong evidence that autologous hematopoietic stem cell transplantation offers superior long-term clinical outcomes compared to two of the most effective current disease-modifying therapies for relapsing multiple sclerosis, particularly in terms of preventing relapses and maintaining sustained clinical benefit over a 5-year follow-up period.

Changes in neurological deficits and improvements in function were compared between two groups for 1 year after symptom onset. Patients treated with autologous MSCs showed significant improvement in both cognition and mobility.

MSC therapy is safe and effective in treating IS by improving the neurological deficits, motor function and daily life quality of patients.

Numerous studies reported better results when the mesenchymal stem cells were used in co-culture with other cells or used in scaffolds. Mesenchymal stem cells were also found to have an immune-modulatory role, which can improve surgical outcome.

All of the children demonstrated neurological improvement, with significant reductions in the number of both epileptic seizures and SE episodes, with an improved quality of life.

This study supports the benefit of intrathecal administration of autologous MSCs for the treatment of neuropathic pain in patients with spinal cord injuries.

Patients receiving MSCs saw significant improvement in standing and walking time, with reduced need for medication.

Injection of imesenchymal stem cells directly into damaged spinal discs reduce back pain and help heal the disc tissue, potentially avoiding the need for surgery. This treatment works best when used early in disc problems and could help keep the spine working normally, preventing further damage and the need for more invasive procedures later.

In certain autoimmune diseases AHSCT can be good choice when conventional therapy failed.

Hematopoietic stem cell transplantation (HSCT) has been proposed as a therapeutic option for patients with Systemic Lupus Erythematosus (SLE) refractory to standard therapy. This therapeutic approach has been applied to other severe autoimmune diseases refractory to standard therapy with promising results.

This study illustrate that quality‐of‐life and functional capacity parameters improve with cell‐based therapy even if classic measures of cardiac function, such as ejection fraction, do not.

Current evidence points toward stem cell therapy as an effective treatment for human patients with DFU

Intravenous transplantation of bone marrow-derived mononuclear cells (BMMCs) successfully improved cognitive function and prevented neurodegeneration in two different Alzheimer's disease mouse models.

As we age, stem cells lose efficacy and ability to heal.

This phase II randomized trial demonstrates that autologous hematopoietic stem cell transplantation (AHSCT) is significantly more effective than mitoxantrone at reducing MRI-detected disease activity in patients with aggressive multiple sclerosis. Results showed a 79% reduction in new T2 lesions and a significant decrease in relapse rates, supporting the need for larger phase III clinical trials.